Skip to main content

Baxter International stock price and financials

  • BAX · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$25.81+0.27%Close 13 Nov 2026
Market value
$13.30B
EV / EBITDA
27.50
Dividend yield
0.8%
Beta · 1 year
1.05
Return · 1 year
+38.0%
52-week range$15.73 — $30.00

Share price close 16 Nov 2026

−0.2%1 monthHigh $26.50Low $23.00
$23$24$25$26$27Q3 FY2026 report filed 29 Oct 202623 Oct29 Oct4 Nov10 Nov16 Nov
+48.7%6 monthsHigh $28.35Low $17.79
$15$20$25$30Q2 FY2026 report filed 30 Jul 2026Q3 FY2026 report filed 29 Oct 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+34.6%year to dateHigh $28.35Low $15.80
$15$20$25$30Q4 FY2025 report filed 12 Feb 2026Q1 FY2026 report filed 30 Apr 2026Q2 FY2026 report filed 30 Jul 2026Q3 FY2026 report filed 29 Oct 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+39.3%1 yearHigh $28.35Low $15.80
$15$20$25$30Q4 FY2025 report filed 12 Feb 2026Q1 FY2026 report filed 30 Apr 2026Q2 FY2026 report filed 30 Jul 2026Q3 FY2026 report filed 29 Oct 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
−27.2%3 yearsHigh $43.77Low $15.80
$10$20$30$40$50Q4 FY2023 report filed 8 Feb 2024Q1 FY2024 report filed 2 May 2024Q2 FY2024 report filed 6 Aug 2024Q3 FY2024 report filed 12 Nov 2024Q4 FY2024 report filed 21 Feb 2025Q1 FY2025 report filed 6 May 2025Q2 FY2025 report filed 5 Aug 2025Q3 FY2025 report filed 4 Nov 2025Q4 FY2025 report filed 12 Feb 2026Q1 FY2026 report filed 30 Apr 2026Q2 FY2026 report filed 30 Jul 2026Q3 FY2026 report filed 29 Oct 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
−45.3%10 yearsHigh $93.14Low $15.80
$0$20$40$60$80$100Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Baxter International reported revenue of $11.2 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 5.7% from fiscal 2024. Net income was −$957 million and diluted earnings per share −$1.87.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $2.98 billion, up 5.0% from a year earlier.

Figures from Baxter International's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 29 Oct 2026.

Against Health Care

Growth
Bottom quarter
Revenue −0.7% a year over five years · 36th of 37
Profitability
Bottom quarter
Return on invested capital -0.3%, five-year average · 37th of 38
Balance sheet
Bottom quarter
Net debt 9.3× EBITDA · 37th of 38

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$11.24B+5.7%
Net income
−$957.0M
Diluted EPS
−$1.87
Gross margin
30.1%−7.4 pts
Free cash flow
$332.0M−42.1%
Net debt
$7.81B−33.1%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
−$5B$0$5B$10B$15BRevenue, FY16: $10.16BNet income, FY16: $4.96BFY16Revenue, FY17: $10.58BNet income, FY17: $602MFY17Revenue, FY18: $11.1BNet income, FY18: $1.55BFY18Revenue, FY19: $11.36BNet income, FY19: $1BFY19Revenue, FY20: $11.67BNet income, FY20: $1.1BFY20Revenue, FY21: $12.15BNet income, FY21: $1.28BFY21Revenue, FY22: $10.06BNet income, FY22: −$2.43BFY22Revenue, FY23: $10.36BNet income, FY23: $2.66BFY23Revenue, FY24: $10.64BNet income, FY24: −$649MFY24Revenue, FY25: $11.24BNet income, FY25: −$957MFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 29 Oct 2026 · Full results →

Revenue
$2.98B+5.0% on a year
Gross margin
33.4%−0.1 pts on a year
Operating income
$225.0M+30.8% on a year
Net income
$294.0M
Diluted EPS
$0.57
Free cash flow
$448.0M+256% on a year

Comparable companies All of Health Care →

Baxter International beside the other S&P 500 members in Health Care Equipment, by market value.

Baxter International and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
Baxter InternationalBAX$13.30B+0.3%+38.0%+5.3%−6.2%—
Abbott LaboratoriesABT$188.1B+1.2%−15.8%+10.0%9.7%40.0
Intuitive SurgicalISRG$152.6B+0.8%−22.5%+20.5%25.5%51.6
Boston ScientificBSX$63.86B+0.3%−57.4%+8.9%16.6%18.2
Edwards LifesciencesEW$61.47B+1.3%+25.2%+13.4%15.3%60.2
Becton DickinsonBDX$59.14B+1.1%+44.4%−2.6%4.5%62.9
Idexx LaboratoriesIDXX$55.78B+0.9%−1.3%+11.9%25.4%47.2

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
-50%0%50%30.1%-2.7%-8.5%FY16FY19FY22FY25

Baxter International revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Baxter International revenue by segment, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025
Medical Products & Therapies (earlier basis)$4.82B$5.01B+4.1%$5.21B+3.9%$5.30B+1.8%
Healthcare Systems & Technologies$2.94B$3.01B+2.5%$2.95B−2.1%$3.07B+4.1%
Pharmaceuticals$2.13B$2.25B+5.8%$2.41B+7.2%$2.49B+3.4%
Other (earlier basis)$177.0M$87.00M−50.8%$67.00M−23.0%$381.0M+469%
Total revenue$10.06B$10.36B$10.64B$11.24B

By region

Baxter International revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$4.94B$5.77B+16.8%$5.80B+0.6%$5.85B+0.8%$6.12B+4.6%
International$7.21B$4.29B−40.5%$4.56B+6.3%$4.79B+5.0%$5.12B+7.0%
Total revenue$12.15B$10.06B$10.36B$10.64B$11.24B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Baxter International income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$10.16B$10.58B$11.10B$11.36B$11.67B$12.15B$10.06B$10.36B$10.64B$11.24B
Revenue growth+2.0%+4.1%+4.9%+2.4%+2.7%+4.1%−17.2%+3.0%+2.7%+5.7%
Gross profit$4.12B$4.47B$4.76B$4.76B$4.59B$4.72B$3.55B$4.15B$3.98B$3.38B
Operating income$745.0M$1.29B$1.58B$1.77B$1.62B$1.35B−$2.85B$707.0M$14.00M−$308.0M
Net income$4.96B$602.0M$1.55B$1.00B$1.10B$1.28B−$2.43B$2.66B−$649.0M−$957.0M
Diluted EPS$9.01$1.08$2.83$1.93$2.13$2.53−$4.83$5.23−$1.27−$1.87
Gross margin40.5%42.3%42.9%41.9%39.3%38.9%35.3%40.1%37.5%30.1%
Operating margin7.3%12.2%14.3%15.6%13.8%11.1%−28.3%6.8%0.1%−2.7%
Net margin48.9%5.7%13.9%8.8%9.4%10.6%−24.2%25.6%−6.1%−8.5%

Cash flow

Baxter International cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$1.65B$1.71B$2.02B$2.10B$1.87B$2.22B$1.21B$1.73B$1.02B$845.0M
Capital expenditure$719.0M$616.0M$659.0M$696.0M$709.0M$691.0M$377.0M$432.0M$446.0M$513.0M
Free cash flow$935.0M$1.10B$1.36B$1.41B$1.16B$1.53B$834.0M$1.29B$573.0M$332.0M

Balance sheet and shares

Baxter International balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$2.80B$3.39B$1.84B$3.33B$3.73B$2.95B$1.72B$3.08B$1.76B$1.97B
Total debt$2.78B$3.51B$3.48B$5.96B$6.80B$18.31B$17.20B$14.11B$13.45B$9.78B
Shareholders' equity$8.29B$9.12B$7.84B$7.88B$8.69B$9.08B$5.83B$8.40B$6.96B$6.13B
Diluted shares551M555M546M519M517M508M504M508M510M513M
Dividends per share$0.51$0.61$0.73$0.85$0.95$1.08$1.15$1.16$1.04$0.52

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Baxter International quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$2.75B$2.63B$2.81B$2.83B$2.97B$2.70B$2.96B$2.98B
Revenue, year on year+0.9%+5.4%+4.3%+5.0%+8.0%+2.9%+5.3%+5.0%
Gross margin34.8%32.8%35.3%33.5%19.4%33.0%34.9%33.4%
Operating income−$435.0M$58.00M$191.0M$172.0M−$729.0M$66.00M$217.0M$225.0M
Net income−$512.0M$126.0M$91.00M−$46.00M−$1.13B−$15.00M$126.0M$294.0M
Diluted EPS−$1.00$0.25$0.18−$0.09−$2.20−$0.03$0.24$0.57
Free cash flow$356.0M−$315.0M$77.00M$126.0M$444.0M$76.00M$169.0M$448.0M

Operating KPIs

The operating figures Baxter International reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Baxter International operating KPIs
KPILatestPeriodChange on a yearRecent periods
Infusion Therapies & Platforms revenue$1.8Bquarter to 30 Sep 2026up 5.3%
Infusion Therapies & Technologies revenue$981.0Mquarter to 31 Mar 2026down 1.3%
Care & Connectivity Solutions revenue$498.0Mquarter to 30 Sep 2026up 5.3%
Advanced Surgery revenue$342.0Mquarter to 30 Sep 2026up 11.8%
Drug Compounding revenue$320.0Mquarter to 31 Mar 2026up 30.1%
Front Line Care revenue$308.0Mquarter to 30 Sep 2026up 2.7%
Injectables & Anesthesia revenue$301.0Mquarter to 31 Mar 2026down 10.1%
Medical Products & Therapies revenue$2.1Bquarter to 30 Sep 2026up 6.3%
Healthcare Systems & Technologies revenue$806.0Mquarter to 30 Sep 2026up 4.3%
Pharmaceuticals revenue$621.0Mquarter to 31 Mar 2026up 6.9%
United States revenue$1.6Bquarter to 30 Sep 2026up 3.3%
International revenue$1.4Bquarter to 30 Sep 2026up 7.0%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Baxter International's revenue in fiscal 2025?

$11.2 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Baxter International's net income in fiscal 2025?

−$957 million for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Baxter International's diluted earnings per share in fiscal 2025?

−$1.87 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Baxter International's gross margin?

30.1% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Baxter International's operating margin?

−2.7% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Baxter International generate in fiscal 2025?

$332 million for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Baxter International's revenue come from?

In fiscal 2025, by segment: Medical Products & Therapies (earlier basis) $5.30B (47%), Healthcare Systems & Technologies $3.07B (27%), Pharmaceuticals $2.49B (22%), Other (earlier basis) $381.0M (3.4%), out of $11.24B in all, as stated in its annual report.

In the terminal

Twenty years of Baxter International's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans